Claims
- 1. A method for treating a cancer in a subject, comprising:
obtaining a mixture of galactomannan polysaccharide and an effective dose of a chemotherapeutic agent in a pharmaceutically acceptable formulation; and administering the formulation to the subject so as to treat the cancer.
- 2. A method according to claim 1, wherein the mixture contains an amount of galactomannan and the therapeutic agent in a ratio suitable for reducing a toxic effect in the subject, the toxic effect associated with administration of the chemotherapeutic agent absent galactomannan.
- 3. A method according to claim 1, wherein the mixture contains an amount of galactomannan and the therapeutic agent in a ratio suitable for enhancing efficacy of chemotherapeutic effect for treating the cancer.
- 4. A method according to claim 1, wherein the size of the galactomannan is in the range of 20,000 to 600,000D.
- 5. A method according to claim 4, wherein the galactomannan has a molecular weight in the range of 90,000 to 415,000D.
- 6. A method according to claim 4, wherein the galactomannan has a molecular weight in the range of 40,000-200,000D.
- 7. A method according to claim 4, wherein the galactomannan has an average molecular weight of 48,000D.
- 8. A method according to claim 4, wherein the galactomannan has an average molecular weight of 83,000D.
- 9. A method according to claim 4, wherein the galactomannan has an average molecular weight of 215,000D.
- 10. A method according to claim 1, wherein the galactomannan is a derivative of an isolate from Gleditsia triacanthos.
- 11. A method according to claim 1, wherein the galactomannan is a derivative of an isolate from Medicago falcata.
- 12. A method according to claim 1, wherein the galactomannan is a derivative of an isolate from Cyamopsis tetragonoloba.
- 13. A method according to claim 1, wherein the galactomannan is β1,4D-galactomannan.
- 14. A method according to claim 4, wherein galactomannan includes a ratio of mannose to galactose in the range of 1.0-3.0.
- 15. A method according to claim 14, wherein galactomannan includes a ratio of 2.6 mannose to 1.5 galactose.
- 16. A method according to claim 14, wherein galactomannan includes a ratio of 2.2 mannose to 0.9 galactose.
- 17. A method according to claim 14, wherein the galactomannan includes a ratio of 1.13 mannose to 1 galactose.
- 18. A method according to claim 14, wherein the galactomannan includes a ratio of 2.2 mannose to 1 galactose.
- 19. A method according to claim 1, wherein the galactomannan and the chemotherapeutic agent are present in the mixture in a ratio of 0.1:1 w/w to 10:1 w/w.
- 20. A method according to claim 2, wherein the mixture has a reduced toxicity of greater than 50% compared with the same dose of the agent absent galactomannan.
- 21. A method according to claim 2, wherein the mixture has a reduced toxicity of greater than 80% compared with the same dose of the agent absent galactomannan.
- 22. A method according to claim 3, wherein the mixture has an enhanced efficacy of greater than 50% compared with the same dose of the agent absent galactomannan.
- 23. A method according to claim 3, wherein the mixture has an enhanced efficacy of greater than 80% compared with the same dose of the agent absent galactomannan.
- 24. A method according to claim 1, wherein the chemotherapeutic agent is adriamycin.
- 25. A method according to claim 1, wherein the chemotherapeutic agent is 5-FU.
- 26. A method according to claim 1, wherein the cancer is any of chronic leukemia, breast cancer, sarcoma, ovarian carcinoma, rectal cancer, throat cancer, melanoma, colon cancer, bladder cancer, lung cancer, mammary adenocarcinoma, gastrointestinal cancer, stomach cancer, prostate cancer, pancreatic cancer, or Kaposi's sarcoma.
- 27. The method according to claim 1, wherein the cancer is any of breast cancer, colon cancer, or pancreatic cancer.
- 28. The method according to claim 26, wherein the subject is a human subject.
- 29. A pharmaceutical formulation, comprising: a mixture of galactomannan polysaccharide and an effective dose for treating cancer of a chemotherapeutic agent in a pharmaceutically acceptable formulation.
- 30. A pharmaceutical formulation, according to claim 29, wherein the mixture contains an amount of galactomannan and the chemotherapeutic agent in a ratio suitable for reducing a toxic effect in the subject, the toxic effect resulting from administration of a cancer treating amount of chemotherapeutic agent absent galactomannan.
- 31. A pharmaceutical formulation according to claim 29, wherein the mixture contains an amount of galactomannan and the chemotherapeutic agent in a ratio suitable for enhancing efficacy of chemotherapeutic effect for treating the cancer.
- 32. A pharmaceutical formulation according to claim 29, wherein the chemotherapeutic agent is 5-FU.
- 33. A pharmaceutical formulation according to claim 29, wherein the chemotherapeutic agent is adriamycin.
- 34. A formulation according to claim 30 and 31, wherein the formulation is in a powder form.
- 35. A formulation according to claim 30 and 31, wherein the formulation is in a liquid form.
- 36. A method for treating cancer in a subject, comprising:
obtaining a mixture of galactomannan polysaccharide and an effective dose of a chemotherapeutic agent formulated so that the chemotherapeutic agent has reduced toxicity in the presence of the galactomannan, the formulation being suitable for parenteral administration to the subject; and administering the formulation to the subject so as to treat the cancer.
- 37. A method for treating cancer in a subject, comprising:
obtaining an effective dose of a mixture of galactomannan polysaccharide and an effective dose of a chemotherapeutic agent formulated so that the chemotherapeutic agent has enhanced therapeutic efficacy in the presence of the galactomannan, the formulation being suitable for parenteral administration to the subject; and administering the formulation to the subject so as to treat the cancer.
- 38. A method according to claim 36 or 37, wherein the chemotherapeutic agent is adriamycin or 5 fluorouracil.
- 39. A method according to claim 38, wherein the enhanced therapeutic effect is a synergistic therapeutic effect.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from, and is a continuation-in-part application of, U.S. patent application Ser. No. 09/818,596, filed Mar. 27, 2001, and also claims priority from U.S. Provisional Application No. 60/317,092 filed Sep. 4, 2001, both of which are herein incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60317092 |
Sep 2001 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09818596 |
Mar 2001 |
US |
Child |
10108237 |
Mar 2002 |
US |